Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 3/20 | 0.36 |
| ▸ | ECE1 | P42892 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042749 | 0.85 | FOLH1 (0.42) | FOLH1SIRT2SIRT1MMEECE1 | |
| SCHEMBL3037406 | 0.83 | FOLH1 (0.42) | FOLH1SIRT2SIRT1MMEECE1 | |
| SCHEMBL3046493 | 0.83 | FOLH1 (0.42) | FOLH1SIRT2SIRT1MMEECE1 | |
| SCHEMBL3054282 | 0.80 | MME (0.43) | FOLH1SIRT2SIRT1MMEECE1 | |
| SCHEMBL3040765 | 0.80 | ECE1 (0.38) | FOLH1SIRT2SIRT1MMEECE1 | |
| SCHEMBL3053901 | 0.80 | FOLH1 (0.40) | FOLH1MMEECE1NAALAD2 | |
| SCHEMBL3050998 | 0.79 | ECE1 (0.43) | FOLH1SIRT2SIRT1MMEECE1 | |
| Trifluoroacetic Acid SCHEMBL3044628 | 0.77 | MME (0.42) | FOLH1SIRT2SIRT1MMEECE1 | |
| Trifluoroacetic Acid SCHEMBL3055444 | 0.75 | ITGB3 (0.43) | FOLH1SIRT2SIRT1MMEECE1 | |
| SCHEMBL3047963 | 0.75 | PPARA (0.41) | FOLH1MMECTSKNAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012153125-A1 | NOVEL COMPOUNDS AND METHODS FOR USE IN MEDICINE | ASTON UNIVERSITY (GB) | 2012-11-15 | — | — | WO | disclosed |
| US-7723307-B2 | Amino acid derivatives and pharmaceutical uses thereof | ASTON UNIVERSITY (GB) | 2010-05-25 | — | — | US | disclosed |
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | ASTON UNIVERSITY (GB) | 2008-08-21 | — | — | US | disclosed |
| EP-1648924-B1 | DIPEPTIDE TRANSGLUTAMINASE INHIBITORS AND METHODS OF USING THE SAME | UNIV ASTON (GB) | 2008-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200511-A1 | Novel Compounds and Methods of Using the Same | F3, IL4I1, TPMT | FOLH1 609/4885SIRT2 2625/4885SIRT1 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.